NCT02953652 · MORE INFO

Limitations, agreements, and source contact

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) · Source last updated 2024-09-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: HUYABIO International, LLC has agreements with PIs and the agreements restricts the right of the PI to discuss or publish trial results after the trial is completed. The content of disclosure restriction stated in the agreement is "PI shall obtain sponsor's prior written consent before disclosing the information obtained from this clinical trial to a professional society or other external party."
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

Complete source fields

certain Agreement

other Details: HUYABIO International, LLC has agreements with PIs and the agreements restricts the right of the PI to discuss or publish trial results after the trial is completed. The content of disclosure restriction stated in the agreement is "PI shall obtain sponsor's prior written consent before disclosing the information obtained from this clinical trial to a professional society or other external party."
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice